Literature DB >> 3894171

Therapeutic benefits from a poorly absorbed prednisolone enema in distal colitis.

P B McIntyre, F A Macrae, L Berghouse, J English, J E Lennard-Jones.   

Abstract

A double blind controlled trial has been conducted in 40 patients to compare the therapeutic effects of prednisolone metasulphobenzoate enemas with those of prednisolone-21-phosphate enemas. Both enemas brought about improvement in symptoms and sigmoidoscopic appearances in more than 70% of patients treated. The absorption of prednisolone from the metasulphobenzoate enema in three patients was less than from the 21-phosphate enema. In view of the low plasma prednisolone concentrations obtained, there are theoretical advantages in using a poorly absorbed enema to avoid the possibility of systemic steroid effects in patients requiring long term steroid treatment.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3894171      PMCID: PMC1432788          DOI: 10.1136/gut.26.8.822

Source DB:  PubMed          Journal:  Gut        ISSN: 0017-5749            Impact factor:   23.059


  5 in total

1.  Intrarectal treatment of 100 cases of ulcerative colitis with prednisolone-21-phosphate enemata.

Authors:  S G MATTS
Journal:  Br Med J       Date:  1961-01-21

2.  A radioimmunoassay method for prednisolone: comparison with the competitive protein binding method.

Authors:  J Chakraborty; J English; V Marks; M C Dumasia; D J Chapman
Journal:  Br J Clin Pharmacol       Date:  1976-10       Impact factor: 4.335

3.  Plasma prednisolone levels and adrenocortical responsiveness after administration of prednisolone-21-phosphate as a retention enema.

Authors:  D A Lee; G M Taylor; V H James; G Walker
Journal:  Gut       Date:  1979-05       Impact factor: 23.059

4.  Plasma prednisolone levels after administration of prednisolone-21-phosphate as a retention enema in colitis.

Authors:  J Powell-Tuck; J E Lennard-Jones; C S May; C G Wilson; J W Paterson
Journal:  Br Med J       Date:  1976-01-24

5.  Rectally administered prednisolone--evidence for a predominantly local action.

Authors:  D A Lee; M Taylor; V H James; G Walker
Journal:  Gut       Date:  1980-03       Impact factor: 23.059

  5 in total
  15 in total

Review 1.  Drug therapy of ulcerative colitis.

Authors:  B Crotty; D P Jewell
Journal:  Br J Clin Pharmacol       Date:  1992-09       Impact factor: 4.335

Review 2.  Optimization of conventional therapy in patients with IBD.

Authors:  Kirstin M Taylor; Peter M Irving
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2011-10-04       Impact factor: 46.802

Review 3.  Drug management of ulcerative colitis.

Authors:  M A Kamm; A Senapati
Journal:  BMJ       Date:  1992-07-04

Review 4.  Clinical pharmacokinetics of prednisone and prednisolone.

Authors:  B M Frey; F J Frey
Journal:  Clin Pharmacokinet       Date:  1990-08       Impact factor: 6.447

Review 5.  A practical guide to the management of distal ulcerative colitis.

Authors:  S Ardizzone; G Bianchi Porro
Journal:  Drugs       Date:  1998-04       Impact factor: 9.546

Review 6.  Medical treatment of inflammatory bowel disease: new therapies, new drugs.

Authors:  L R Sutherland
Journal:  CMAJ       Date:  1987-11-01       Impact factor: 8.262

Review 7.  Risk-benefit assessment of drugs used in the treatment of inflammatory bowel disease.

Authors:  S B Hanauer; G Stathopoulos
Journal:  Drug Saf       Date:  1991 May-Jun       Impact factor: 5.606

8.  5-Aminosalicylic acid enemas in treatment of distal ulcerative colitis and proctitis in Canada.

Authors:  L R Sutherland; F Martin
Journal:  Dig Dis Sci       Date:  1987-12       Impact factor: 3.199

9.  Oral fluticasone propionate in active distal ulcerative colitis.

Authors:  P Angus; J A Snook; M Reid; D P Jewell
Journal:  Gut       Date:  1992-05       Impact factor: 23.059

Review 10.  Comparative tolerability of therapies for ulcerative colitis.

Authors:  Sandro Ardizzone; Gabriele Bianchi Porro
Journal:  Drug Saf       Date:  2002       Impact factor: 5.606

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.